Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 5/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 2/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116678 | 0.84 | LMNA (0.68) | LMNATSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL16487095 | 0.82 | LMNA (0.44) | LMNATSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL3122714 | 0.81 | LMNA (0.46) | LMNATSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL11980432 | 0.81 | MAP4K4 (0.42) | LMNATSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL3466463 | 0.81 | LMNA (0.46) | LMNATSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL16486560 | 0.80 | TYMS (0.46) | LMNATSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL1669646 | 0.80 | ERBB2 (0.40) | LMNATSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL4342949 | 0.80 | HSP90AA1 (0.53) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL5132693 | 0.79 | LMNA (0.74) | LMNATSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL18786153 | 0.79 | NUDT1 (0.43) | LMNATSHRPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2020-04-02 | — | — | US | disclosed |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-09-24 | — | — | US | disclosed |
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-07-07 | — | — | US | disclosed |
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2016-07-07 | — | — | US | disclosed |
| WO-2015023976-A2 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194328-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885PI4KA 1654/4885 |
| US-10421758-B2 | Selective Grp94 inhibitors and uses thereof | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885PI4KA 1654/4885 |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | LMNA 4007/4885TSHR 3978/4885PI4KA 2175/4885 |
| US-20200102312-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885PI4KA 1654/4885 |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | LMNA 4391/4885TSHR 3467/4885PI4KA 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.